NCT06481345进行中（未招募）不适用
Characterization of Myeloproliferative Neoplasia With a Mutated IDH, SRSF2 or SF3B1 Allele
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 300
- 试验地点
- 1
- 主要终点
- Event free survival
研究概览
简要总结
Retrospective study assessing the impact of IDH1/2, SRSF2 or SF3B1 mutations on event free survival of MPN patients
详细描述
Patients with a diagnosis of MPN and a mutation of IDH1/2, SRSF2 or SF3B1 will be included. Clinical and biological characterisation at diagnosis, as well as evlution will be recorded. Event free survival will be assessed in each group (event = thrombosis, transformation to mylofibrosis/acute leukemia, death).
研究设计
- 研究类型
- Observational
- 观察模型
- Case Control
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with MPN diagnosis
- •Mutation in IDH1/2, SRSF2 or SF3B1
排除标准
- •Unable to consent
结局指标
主要结局
Event free survival
时间窗: 3 years
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
招募中
不适用
Ferroptosis Study in SF3B1-mutant Myelodysplastic Syndromes (FerMDS)Myelodysplastic SyndromesFerroptosisNCT05924074University Hospital, Bordeaux80
已完成
2 期
Combined Ruxolitinib and Enasidenib in Patients With Accelerated/Blast-phase Myeloproliferative Neoplasm or Chronic-phase Myelofibrosis With an IDH2 MutationAccelerated/Blast-phase Myeloproliferative NeoplasmChronic-phase MyelofibrosisIDH2 MutationNCT04281498John Mascarenhas6
Unknown
不适用
Defining the Molecular Risk in Israeli Patients With Secondary Compared to Primary MyelofibrosisMyelofibrosis, PrimaryMyelofibrosis, Post PVMyelofibrosis, Post ETNCT03402399Assaf-Harofeh Medical Center222
招募中
不适用
Monitoring Mutational Burden in Low Risk MDS Patients Using Sequential Peripheral Blood SamplesMyelodysplastic SyndromesNCT04251078Josep Carreras Leukaemia Research Institute200
已完成
不适用
Genetic abnormalities in myeloproliferative neoplasmsJPRN-UMIN000016132Mie University, Department of Hematology and Oncology50